Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 8,098 shares at $20.04 ($162K) on 2023-06-07, disclosed to the SEC on 2023-06-09.
Scheduled sale ($162k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.04 | 4,049 | $81K | 50.0% |
| 2 | $20.04 | 4,049 | $81K | 50.0% |
| Total | $20.04 avg | 8,098 | $162K | 100% |
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |